Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
The data driven fertility company helps increase the success rate of fertility treatments
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Both companies have been selected for stand-by production by German government
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Subscribe To Our Newsletter & Stay Updated
